I don't think much of Zavesca its sales and label are not very strong, though I don't have your background to comment from a scientific standpoint. I had seen side effects I believe due to its non-selective nature where quite high.
I was looking at some of my old TKT stuff and I don't know if Shire had some setbacks but their time-line for GAGCB is a lot longer then what TKT had talked about.
For the poster who asked the Zacks blurb on Amicus I don't think much of Zacks reports. I saw an early one and will give them credit for having some detail and industry comp's, but basically they pulled a bunch of stuff from their filings and/or presentation. The actual analysis seemed lacking IMO. I am still quite long Amicus and am more curious at what some of the Oral Small molecules do rather then the ERT's. A fund has been really supporting the price the past few months (not there is much volume).
Market Data 
Markets 
AI
